Nanotherapeutics to host interactive mini-symposium about Monoclonal Antibody Technology
On March 21st, 2016, Nanotherapeutics will host an interactive mini-symposium devoted to the use of Monoclonal Antibody Technology for Development of Medical Countermeasures. Specific emphasis will be on the development of monoclonal antibodies against Botulinum Neurotoxins, as part of the Advanced Development and Manufacturing of Antibody Technologies (ADAMANT) concept. This meeting will take place at the Nanotherapeutics-Maryland office located at 8490 Progress Drive, Suite 150, Frederick, MD 21701. The meeting will begin at 10:00 a.m. and will conclude at 1:00 p.m.
Our speakers will be James D. Marks, M.D., Ph.D., Professor of Anesthesia and Pharmaceutical Chemistry at UCSF and Chief of Anesthesia and Vice Chairman of Anesthesia and Perioperative Care at San Francisco General Hospital Staff, UCSF, Milan T. Tomic, Ph.D., Senior Director of Antibody Development at Nanotherapeutics and formerly Program Director of Biodefense at XOMA and Robert V. House, Ph.D., Senior Vice President of Government Contracts at Nanotherapeutics.
Emil von Behring’s discovery of anti-toxins to diptheria, tetanus, and anthrax in 1901 eventually led to the discovery of antibodies. More than a century later, the use of therapeutic antibodies has become one of the fastest growing areas of the pharmaceutical industry. Numerous monoclonal antibodies have been approved for several clinical indications with most being developed as treatments for cancer or immunological disorders. Yet ironically, the development of monoclonal antibodies (mAb) against infectious diseases has been slow compared to most other fields. Human Genome Sciences is currently providing stockpiles of Raxibacumab (ABthrax), a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen, to the US government for use in the prevention and treatment of inhaled anthrax. The availability of countermeasures against infective bacteria and viruses has become more important and the development of monoclonal antibodies is a significant advance in this area.
MAbs for treatment or prevention of botulism must have high potency to protect against the major serotypes and sub-serotypes of the toxin. To address this, Prof. James D. Marks’ lab, at UCSF, has been working for more than 15 years with DoD and NIH funding to develop recombinant human mAbs for the treatment and prevention of botulism. Work in Dr. Marks’ lab has shown that combining three mAbs which bind at non-overlapping epitopes, leads to highly potent BoNT neutralization. Dr. Marks will present his antibody discovery work and recent discoveries in the Mechanism of Action for the anti-botulinum antibodies.
Building on the discovered antibodies, XOMA has developed a platform that allows for production of multi-antibody products including a nine antibody co-mixture. Success in developing a lyophilized high-temperature-stable nine-antibody co-formulated product through proof of concept stage has been an industry evolution in approach. Dr. Tomic will present the results of the innovations and establishment of platform processes which has realized in an approximately two to three-fold increased cost efficiency in production, including a significant reduction in time to product.
Traditional antitoxins are not renewable resources and each lot will vary in antibody composition, potency, and possibly safety profile. Oligoclonal antibody drug products overcome these limitations and are recognized as a significant advancement for therapeutic or prophylactic product development approach. Nanotherapeutics’ exclusive license to the oligoclonal antibody technology, and their collaboration with Dr. Marks at UCSF, enables further advancement in Drug Product Medical Countermeasure development and delivery.
For registration details, please contact Ms. Samantha Ruben at
386-462-9663 x7148 or email@example.com